Table 8 Comparison of the incidence of gastrointestinal adverse reactions in the two groups.
From: Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study
Variables | Baseline | P | 2-month | P | ||
|---|---|---|---|---|---|---|
Non-hyperglycemia (n = 525) | Hyperglycemia (n = 266) | Non-hyperglycemia (n = 509) | Hyperglycemia (n = 242) | |||
Nausea | 32 (6.1) | 20 (7.5) | 0.445 | 36 (7.0) | 21 (8.8) | 0.398 |
Vomiting | 11 (2.1) | 7 (2.6) | 0.633 | 3 (0.6) | 5 (2.2) | 0.046 |
Diarrhea | 14 (2.7) | 6 (2.3) | 0.728 | 7 (1.3) | 9 (4.0) | 0.021 |
Abdominal Distension | 7 (1.3) | 13 (4.9) | 0.003 | 19 (3.6) | 10 (4.4) | 0.634 |
Constipation | 9 (1.7) | 10 (3.8) | 0.076 | 16 (3.0) | 29 (12.8) | < 0.001 |
